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Safe and effective use of intensive insulin therapy is challenging for pediatric patients with
diabetes and their caregivers [1]. Parents/caregivers must consider numerous factors such as
variable dietary intake, exercise, school activities, intercurrent illnesses, and changes in
metabolism with growth and puberty when selecting and adjusting insulin doses for the
management of type 1 diabetes (T1D) [2–7]. Despite advanced therapeutic options for the
management of T1D in childhood, the majority of youth fail to achieve glycemic targets of
hemoglobin A1c values,7.5% [8]. Fear of hypoglycemia by caregivers may lead to avoidance
of “lows” in exchange for higher glucose values [9–11].
Studies showed improved glycemic control without increased hypoglycemia in pediatric
patients with diabetes using real-time continuous glucose monitoring (rtCGM) [12–16];
however, these benefits were observed mainly in patients who consistently used their device
for 6 or more days per week [13, 14, 17]. As accuracy and ease of use of rtCGM devices has
improved with newer devices, many persons with T1D and some parents/caregivers of youth
with T1D increasingly rely on rtCGM data to select and adjust insulin doses [18].
In December 2016, the US Food and Drug Administration further improved usability with
the approval of the Dexcom G5 Mobile CGM system (Dexcom G5, Dexcom, Inc., San Diego,
CA) for nonadjunctive insulin dosing for patients aged 2 years and older. Although treatment
algorithms for utilizing CGM data to establish insulin dosing parameters have been used in
earlier clinical trials [19–21], recommendations for using rtCGM trend arrow data non-
adjunctively in routine care are lacking.
Abbreviations: CF, correction factor; ICR, insulin-to-carbohydrate ratio; MDI, multiple daily injection; rtCGM, real-time continuous
glucose monitoring; T1D, type 1 diabetes.
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Notably, there are four previously published methods for using trend arrow data to adjust
insulin doses [21–24]. However, each method has limitations in its complexity and utility.
The purpose of this perspective is to provide safe, practical guidance for using rtCGM trend
arrow data to adjust insulin doses in pediatric patients with T1D, aged 2 years and older,
assuming the use of currently available rapid-acting insulin analogs.We base our approach on
previous algorithms used in clinical trials [19–21], our clinical experiences as endocrinolo-
gists, and guidance from other diabetes specialists [23, 25, 26]. Notably, the Klonoff/Kerr
formula was published following the development of our guidance and was therefore not used
in our comparisons; however, we note the similarities to our own approach and differences in
application. Specifically, we aim to address the needs of clinicians treating pediatric patients
using the Dexcom G5, which is the only system currently approved for nonadjunctive use for
insulin dosing in pediatric patients. It is likely that othersmay be approved in the near future,
especially following the recent Food andDrug Administration approval of the FreeStyle Libre
Flash Glucose Monitoring System for nonadjunctive use in patients ages 18 and older [27].
We recognize our own approach has certain limitations. Currently, there are no clinical
trials that have used the approach we provide. We also recognize that other CGM systems,
although not yet approved in the United States for nonadjunctive use in pediatric patients,
are available and provide useful information based on trend arrows, and we expect that
additional nonadjunctive CGM systems will become available in the near future. It is im-
portant to note that there are no standard conventions for displaying rates of change in-
formation in CGM devices and trend arrows often display rates of change differently; future
standardization would be helpful.
The suggested approach is a starting point of an iterative discussion on how to best use the
Dexcom G5 trend arrow data, which has held nonadjunctive insulin dosing approval since
December 2016.Wehope that our approachwill be useful for futureCGMsystems considering
that the transfer, display, and meaning of trend arrow data may be specific for each brand.
1. Safe and Effective rtCGM Use: Selection of Patients and
Education/Training
Recognizing which patients are most likely to benefit from rtCGM and being able to provide
adequate education are paramount to the success of rtCGM. Use of rtCGM is recommended
for pediatric patients with T1D treated with multiple daily injections (MDIs) or insulin pump
therapy, especially for youth with severe hypoglycemia, nocturnal hypoglycemia, hypogly-
cemia unawareness, those not meeting recommended glycemic targets, and those wanting to
improve glycemic control [28–32]. Table 1 outlines patient considerations.
Education on using rtCGM is a lengthy topic on its own. However, we highlight the im-
portance of teaching patients and parents/caregivers the fundamentals of sensor insertion,
sensor lag time, calibration, and setting alerts, as well as providing patients and parents/
caregivers with realistic expectations (e.g., rtCGM will not eliminate the need for checking
fingerstick glucose levels). Table 2 presents a suggested list of education topics [33–35]. Table
3 lists common medications containing acetaminophen, which is an important consideration
when using rtCGM.
2. Data Sharing
Data sharing is an important feature of rtCGM, and the Dexcom G5 Mobile and Follow apps
allow patients to share real-time datawith up to five individuals. The apps require compatible
smart devices for both the user and individuals monitoring remotely. Dexcom G5Mobile only
requires Bluetooth capability and can useWi-Fi to send data, and Dexcom Follow can receive
data via Wi-Fi, obviating the need for costly mobile data plans for young patients sharing as
well as adult caregivers who want to “follow.”
Use of data sharing varies, especially across the pediatric age span. It is the clinical opinion
and experience of the authors that parents/caregivers of very young children often value
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remote monitoring to help supervise diabetes management. For school-age patients, data
sharing can link patients, parents, school staff, and/or after-school caregivers, underscoring
the importance of education across caregivers. Indeed, recommendations regarding rtCGM in
school settings with variable staffing require attention and guidance. Finally, in adolescent
patients, rtCGM data sharing with parents requires “rules of engagement”with the intended
goal of monitoring for safety rather than “policing” behavior [16].
3. How to Use Trend Arrows to Adjust Insulin Dose
At a basic level, patients requiring intensive insulin therapy rely on the current glucose value,
target glucose value, food intake (if any), and insulin dosing parameters [insulin-to-
carbohydrate ratio (ICR) and correction factor (CF); also known as insulin sensitivity] to
calculate insulin doses when bolusing for carbohydrate intake and/or corrections. This
standard glucose “point in time”monitoring is limited; the glucose value used for calculating
insulin dose is an isolated, static measurement.
Trend arrows add context to this static measurement. Instead of standard “point in time”
monitoring, trend arrows allow individuals to “anticipate” future glucose levels and proac-
tively adjust the insulin dose and food intake based on the directionality of trend arrows.
Upward trend arrows indicate rising glucose levels and may suggest a need for additional
insulin; downward trend arrows indicate falling glucose levels andmay suggest a need for less
insulin, or possible carbohydrate intake. This conceptual shift from “point-in-time” moni-
toring to “anticipating” future glucose levels is essential to using rtCGM optimally. Figure 1
provides an example of how these trend arrows appear and the anticipated glucose change
they represent in Dexcom G5 displays [i.e., Dexcom Receiver and Dexcom smart device apps
(Dexcom G5 Mobile and Dexcom Follow)].
Most importantly, adjusting insulin doses using trend arrows does not replace standard
calculations. Adjusting, or fine tuning, the insulin dose using trend arrows is an additional
step that increases or decreases the insulin dose that has been calculated using standard
parameters. There are caveats—as there arewith all diabetesmanagement approaches—and
the extent of insulin dose adjustment may be impacted by common factors such as meal
composition, time since lastmeal, insulin-on-board, and exercise among other considerations.
We recommend patients become as comfortable as possible with the general application of
rtCGM data and learn how their body responds to various meals (quantity/composition) and
physical activity before applying any approach to adjusting insulin doses using trend arrows.
Table 1. Considerations for Recommending rtCGM
Patients Meeting One or More of the Following Criteria May Be Considered for rtCGM:
► Patient is 2 years of age or greater
► Currently treated by intensive insulin therapy
► Experiencing frequent hypoglycemia
► Hypoglycemia unawareness
► Excessive glucose variability
► Varying and/or intensive activity
► Desire to improve glycemic control
► Understands behaviors that influence glycemic control
► Willing and able to use rtCGM on a nearly daily basis
► Willing and able to learn how to use device and receive ongoing education
► Pregnant or wants to get pregnanta
The following is not an exhaustive list of considerations. It is based on prior publications by the Endocrine Society and
American Association of Clinical Endocrinologists, as well as the clinical experience of the authors. A foundation
criterion is that a patient/parent/guardian or caregiver must be willing and able to understand, use, and learn more
about rtCGM.
Abbreviation: rtCGM, real-time continuous glucose monitor.
aCurrently, no rtCGM system is indicated for use in pregnancy.
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4. Previous Methods to Adjust Insulin Dose Using Trend Arrows
To date, there are four previously published methods to adjust insulin doses using trend
arrows: DirecNet Applied Treatment Algorithm [21], Scheiner method [22], Pettus/Edelman
method [23], and Klonoff/Kerr formula [24]. Notably, the DirecNet, Scheiner, and Klonoff/
Kerr methods include CGM systems other than Dexcom in their approach.
In brief, the DirecNet method determines insulin dose adjustment by calculating percent
increase/decrease based on trend arrow directionality. Notably, the net increase/decrease
will vary depending on food intake because the DirecNet method considers total insulin
dose—e.g., meal and correction dose as appropriate—when determining percent insulin
adjustment. The Scheiner and Pettus/Edelman methods use a different approach. Both use
anticipated glucose values to recommend an adjustment in insulin dose. The patient can then
use predetermined CF and the recommended corrective parameter to add or subtract insulin
based on insulin sensitivity. Although the twomethods have a similar approach, the Scheiner
method has more conservative recommendations for correction parameters to use in insulin
adjustment. The recently published Klonoff/Kerr formula offers a simplified approach by
using rate of change midpoints for each trend arrow scenario and extrapolating anticipated
glucose in the next 45 minutes [24]. Simplified insulin dose adjustments are provided as
insulin units, which is similar to our approach. To assess potential safety, the authors
consider the impact of insulin dose adjustments using minimum total daily insulin doses and
Table 2. Education Checklist When Using rtCGM
The Following are Fundamental Principles and Skills That a Patient and/or Caregiver Should Learn
When Using rtCGM. At the End of Training, Patients and/or Caregivers Should be Able to:
❑ Describe the difference between interstitial fluid and capillary glucose and understand the meaning of lag time.
❑ Recognize the importance of handwashing prior to fingerstick monitoring.
❑ Summarize the calibration procedure and explain when calibration is needed.a
❑ Summarize the limitations in rtCGM data accuracy within the first 24 hours following insertion and beyond the
manufacturer’s recommended wear time.b
❑ Demonstrate the procedures for setting alarms/alerts.c
❑ Explain the significance of alarms/alerts, glucose trend data, and trend arrows in making treatment decisions.c
❑ Explain how to use trend arrows in individualized treatment decisions.
❑ Explain the dangers associated with frequent insulin dosages following meals (i.e., “stacking”).
❑ Explain how to use rtCGM during sick days or illness.d
❑ Explain individualized monitoring and treatment strategies during exercising (e.g., temporary basal rates, insulin
adjustment, carbohydrate adjustment, adjusting for trend arrows).
❑ Demonstrate sensor insertion procedure and list appropriate insertion sites.b
❑When share functions are available: Demonstrate the procedure for uploading the rtCGMdata (e.g., via DexcomG5
Mobile app or Dexcom Clarity) and with others (e.g., Dexcom Follow app or Dexcom Clarity for clinics).e
Abbreviations: rtCGM, real-time continuous glucose monitor.
aThe Dexcom G5 device should be calibrated twice daily according to the manufacturer’s instructions. Persons who
check fingersticks frequently should be informed to not enter every fingerstick value. It is important that patients use
the proper fingerstick monitoring technique (e.g., thoroughly washing hands with soap and water before checking).
Dexcom G5 calibration is reliant on a properly functioning and accurate blood glucose meter. Therefore, we rec-
ommend patients use blood glucose meters with proven accuracy and performance.
bDexcom recommends that sensors be placed in subcutaneous tissue on the abdomen and upper buttock (including
lipohypertrophic areas); however, a recent study found comparable accuracy with placement on the back of the arm
[33]. Importantly, patients should be instructed not to rely solely on their rtCGM data during first 24 hours after
inserting the sensor.
cWhen reviewing alarms/alerts, it is important to discuss how to deal with “alert fatigue,”whichmay prompt patients
to switch them off or underutilize their rtCGM system.
drtCGMcan be used during periods of illness butwill require additional confirmatory fingerstick checks. Importantly,
patients should be cautioned about use of medications that contain acetaminophen, which can cause the rtCGM
system to display false high readings for up to and beyond 6 hours following ingestion [34, 35].
eIf the patient chooses to use data sharing, it is important that caregivers receive training in rtCGM use, specifically,
use of trend arrows, interpretation, and appropriate response.
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the 1500 and 1960 rules to infer correction doses [36]. In the Klonoff/Kerr calculations, the
proposed doses reflect a limited range of CF values and/or total daily insulin doses, which
restricts more insulin-sensitive individuals from applying adjustments. It is the clinical
experience and opinion of the authors that the Klonoff/Kerr formula, presumably most ap-
plicable for adults,may not apply as readily to the pediatric population given thewide range of
insulin sensitivities seen in pediatric patients. Due to the limited application across a broad
range of insulin sensitivities and the fact that we did not consider their formula in the de-
velopment of our approach, we have not included the Klonoff/Kerr formula in our illustrated
comparisons. Figure 2 provides a comparison of the DirecNet, Scheiner, and Pettus/Edelman
methods; the Klonoff/Kerr formula is described above.
Despite some differences, insulin adjustments for prandial and correction insulin doses are
relatively similar and appear to be safe among the described approaches. Each method
appears to offer a safe and effective approach to adjusting insulin doses using trend arrows.
However, these approaches are limited by their complexity and need for numeracy skills.
Additionally, the Scheiner and Pettus/Edelman methods indirectly ask individuals to enter
information that is different from actual measurement into their records and do not take into
consideration the limitation of MDI users with minimum insulin dose increments/decrements
of 1.0 or 0.5 U as well as the need for rounding insulin doses. For the Scheiner and Pettus/
Edelmanmethods,we recognize that bolus calculators, either as an integrated tool in an insulin
pump or as a standalone app, can be used to overcome the challenge of requiring additional
calculations. However, thesemethodsmay be overly reliant on use of bolus calculators, and as a
related concern, clinicians should be aware of the apps their patients use to calculate insulin
doses. It is the clinical opinion of the authors that many bolus calculator apps have not been
rigorously evaluated for accuracy and performance [37]. The Klonoff/Kerr formula takes a
similar approach to ourmethodbyprovidingadjustments in insulinunits; however, the formula
has limitations in the pediatric population where there is a broad range of insulin sensitivities.
5. New Approach to “Adjusting for the Arrows” in Pediatric Patients
We preferred the Scheiner and Pettus/Edelman methods because they rely on insulin
sensitivity and recognize the CF asmost important when adjusting insulin dose using trend
Table 3. Commonly Used Over-the-Counter and Prescription Medications Containing Acetaminophen
Common Over-the-Counter Medicines Containing Acetaminophena
► Actifed® ► Dayquil® ► Midol® ► Sudafed®
► Alka-Seltzer Plus LiquidGels® ► Dimetapp® ► Nyquil® ► Theraflu®
► Anacin® ► Dristan® ► Panadol® ► Triaminic®
► Benadryl® ► Excedrin® ► Robitussin® ► TYLENOL® Brand Products
► Cepacol® ► Feverall® ► Saint Joseph® ► Vanquish®
► Contac® ► Equation 44® ► Aspirin-Free Singlet® ► Vicks®
► Coricidin® ► Goody’s® Powders ► Sinutab® ► Zicam®
► Liquiprin
Common Prescription Medicines Containing Acetaminophena
► Endocet® ► Lortab® ► Tylenol® with Codeine
► Fioricet® ► Percocet® ► Tylox®
► Hycotab ► Phenaphen® ► Ultracet®
► Hydrocet® ► Sedapap® ► Vicodin®
► Hydrocodone Bitartrate ► Tapanol® ► Zydone®
Acetaminophen is known to interfere with certain rtCGM sensors causing falsely high glucose readings. Patients
using rtCGM are cautioned to check with the manufacturer’s information and review labels of over-the-counter
medicines for acetaminophen and to ask their provider and/or pharmacist whether their prescribed medication(s)
contain acetaminophen.
aIncludes store and other generic brands.
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arrows. Therefore, in pediatric patients, we sought a simplified approach that addresses the
limitations described above while accounting for the wide range of insulin sensitivities
observed in the pediatric population. Figure 3 outlines our approach, which is based on
typical insulin sensitivity ranges for pediatric patients. For each insulin sensitivity range,
we suggest an insulin dose adjustment in insulin units rather than as corrective values. In
this manner, insulin adjustments can be more simply added or subtracted to standard
calculations and can be used with MDI or insulin pump therapy. The adjustments also take
into consideration the limitations of 0.5-U increment/decrementminimums forMDI-treated
individuals. Figure 4 is a visual comparison of insulin dose adjustments according to
previous methods based on anticipated glucose (Scheiner and Pettus/Edelman) and our
suggested approach based on insulin sensitivity ranges (Endocrine Society approach). The
illustration shows that our approach aligns well with existing methods that indirectly use
insulin sensitivity to adjust insulin doses while overcoming some of the limitations (e.g., a
need for additional calculations and theminimum increments/decrements possible forMDI-
treated patients).
Our approach divides insulin dose adjustments into five insulin sensitivity ranges that
relate to pediatric developmental stages: $125 (highly sensitive, often used in toddlers/
preschoolers), 75 to ,125 (sensitive, often used in young school-age children), 50 to ,75
(fairly sensitive, generally used in older school age children), 25 to ,50 (less sensitive,
often used in young, early pubertal teens), and ,25 (least sensitive; generally used in
pubertal teens). Patients or parents/caregivers calculate the insulin dose using standard
information (i.e., current glucose value, ICR, and CF) and can then add or subtract insulin
based on trend arrow information and the patient’s insulin sensitivity (e.g., CF) using
these suggestions as a starting point. In the event of adjusting insulin dose for downward
arrows results in a negative insulin dose, the individual or parent/caregiver should
consider if fast-acting carbohydrate is warranted based on the current sensor glucose,
taking into account previous exercise and/or anticipated exercise. We provide several
Figure 1. Dexcom G5 trend arrows. Dexcom G5 presents trend arrow data as icons on the
Dexcom G5 Receiver and on the Dexcom G5 Mobile and Follow mobile apps (App) on
compatible smart devices. According to the manufacturer, trend arrows indicate rates of
glucose change (mg/dL per minute) and can be described as the anticipated glucose change in
30 minutes. Notably, the FLAT arrow (➡) indicates steady but does not indicate zero change.
Note that trend arrows are determined by recent rtCGM measurements (generally the most
recent 10 minutes of glucose values). In general, anticipated glucose may be less accurate
when trying to predict changes over extended periods of time (e.g., beyond 20 to 30 minutes)
due to the many factors that may influence glucose levels. Conversion: mg/dL30.0555=mmol/L.
1466 | Journal of the Endocrine Society | doi: 10.1210/js.2017-00389
additional case examples to illustrate how our approach may be used in real-life scenarios
in Table 4.
Patients and parents/caregivers should individualize adjustments based on the sugges-
tions, according to the patient’s CF, and subsequent observation of responses to dose ad-
justments. For missed boluses and miscalculations, patients and parents/caregivers should
not use the suggested approach to adjust for trend arrows. Instead, they should take the
insulin dose calculated from the glucose value at the time of the food consumption and use
their ICR, preferably within 2 hours of the missed dose. Adjusting insulin doses using trend
arrows should also be avoided in cases of underestimating carbohydrate intake (i.e., mis-
calculations) and overcorrecting for hypoglycemia with fast-acting carbohydrate. At these
times, the trend arrows can serve an important role as reminders to patients/families of a
missed dose or a miscalculation.
6. Safety
Insulin stacking (i.e., repeated injection of bolus insulin correction doses at close intervals
when glucose-lowering of initial insulin bolus dose is ongoing) can lead to hypoglycemia;
thus, it is important to avoid additional insulin bolus dosing when patients/parents/caregivers
Figure 2. Other methods to adjust insulin doses using trend arrows. Three published
methods for adjusting insulin dose using rtCGM trend arrow data are compared [DirecNet
(Abbott system) [21], Scheiner (Medtronic and Dexcom systems) [22], and Pettus/Edelman
(Dexcom system)] [23]. The DirecNet method takes total insulin dosage, including
carbohydrate consumption (if any) into consideration. Scheiner and Pettus/Edelman methods
are based on anticipated change in blood glucose with the Scheiner method being more
conservative in insulin adjustment. Notably, the author of the Scheiner method has
presented slightly modified values in recent presentations (personal communication) relative
to past publication [22]. We use the more recently presented values in this comparison. All
three require calculations beyond managing the correction and carbohydrate consumption. All
three assume the patient has insulin requiring diabetes and is using rapid-acting insulin for
meals and correction doses. Note that the recently published Klonoff/Kerr formula recommends
adjusting insulin doses by 1, 1.5, or 2 U supplements/decrements for rates of change of 1 to 2,
2 to 3, and .3 mg/dL/min, respectively [24]. Conversion: mg/dL30.0555=mmol/L.
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Figure 3. New approach to adjust insulin doses using trend arrows in pediatric patients
with diabetes. This figure outlines our approach to adjusting insulin doses using trend arrow
data from the Dexcom G5 system in pediatric patients with diabetes receiving rapid acting
insulin analogs. The approach is based on anticipated glucose change and typical insulin
sensitivity ranges in pediatric patients that correspond to developmental stages. It should be
noted that insulin sensitivity is generally greater in younger, prepubertal patients and
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see rapid rises in postprandial glucose values using rtCGM, especially if there is sub-
stantial insulin on board. Rapid increases in glucose levels can be especially problematic if
insulin is given postprandially, as may be the case in very young children [38]. In general,
we suggest pediatric patients using rapid-acting insulin analogs wait at least 3 hours after
the prandial bolus before giving a subsequent correction dose. For individuals using an
insulin pump, this assumes active insulin duration of at least 3 hours. For pediatric
patients, especially younger patients, who tend to “graze” throughout the day, dose ad-
justments using trend arrows can potentially lead to undue insulin stacking with risk of
hypoglycemia and should be avoided. Importantly, our approach is designed for premeals
and 3 or more hours postprandially.
7. Important Considerations When “Adjusting for the Arrows”
We recognize insulin dosing decisions at bedtime, with exercise, and during sick day man-
agement are complex and multifactorial. During these special circumstances, food intake,
physical activity, and stressors among other factors impact insulin dosing decisions. We
reiterate that our suggestions are not comprehensive in these special circumstances and
should serve as a starting point for future discussion. We recognize these areas are of great
concern and further consideration on how our suggested approach may apply under these
circumstances needs to be addressed in the near future.
A. Bedtime
Nocturnal hypoglycemia is common and potentially dangerous, particularly when pa-
tients engage in intensive physical activity during the day. Children also tend to be deeper
sleepers, engage in sporadic unpredictable exercise, experience changingmetabolism, and
may have blunted overnight counter-regulatory hormone responses, which puts them at
increased risk for nocturnal hypoglycemia compared with adults [39]. We recommend a
bedtime glucose target of ~130mg/dL with a FLAT or ANGLEUP trend arrow [21]. Other
trend arrows may provide guidance in determining a bedtime snack or correction bolus.
For example, if bedtime glucose levels are near target and are accompanied by downward
trending arrows, an extra snack may be needed. Conversely, a modest correction might
be given if glucose levels are over target and accompanied by upward arrows. Although
our approach to adjustments may be considered at bedtime, patients and parents/
caregivers should use caution when adding insulin at that time, with follow-up as-
sessment of glucose levels overnight as indicated. Patients or parents/caregivers should
also consider altering the CGM alerts for trend arrows and/or the high/low threshold
alert levels following a day of atypical physical activity or illness to reduce glucose levels
out of range.
decreases over time as youth age with decreasing insulin sensitivity associated with pubertal
growth and development. The approach to adjusting insulin doses using trend arrows is
suggested for premeal boluses and for corrections 3 or more hours following a meal. In
general, the authors recommend avoiding adjustments using trend arrows immediately
following meals due to the variability that ingested carbohydrates can have on trend arrows.
Generally, one should begin with conservative adjustments to understand how the dose
changes impact the individual. It is essential to understand that adjusting insulin doses
using trend arrows does not replace but adds to standard calculations using ICR and CF. The
approach assumes the patient has insulin requiring diabetes, is using rapid-acting insulin for
meals and correction, and is using ICR and CF factors that have been accurately determined
by the patient’s health care team (e.g., determining CF using the 1500 to 1800 rule) [36].
Conversion: mg/dL30.0555=mmol/L. CF, correction factor in mg/dL, indicates glucose
lowering per unit of rapid-acting insulin; U, units of rapid-acting insulin.
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B. Exercise/Physical Activity
Exercise is a fundamental component of diabetes management and paramount to children’s
well-being. rtCGM trend arrows and alerts/alarms are particularly beneficial before, during,
and after exercise/physical activity. These features alert patients and parents/caregivers to
rapid changes and onset of hypoglycemia, which are less noticeable during exertion. The
alerts and alarms also provide overnight safety following a day of intense exercise/physical
activity by detecting nocturnal hypoglycemia.
Figure 4. Sensitivity comparison of CF based methods to adjust insulin doses using trend
arrows in pediatric patients. The figure is a visual comparison of insulin dose adjustments
according to previous methods based on anticipated glucose (Scheiner and Pettus/Edelman)
and our suggested approach based on insulin sensitivity ranges (Endocrine Society approach).
The illustration shows that our approach aligns well with existing methods that indirectly
use insulin sensitivity to adjust insulin doses while overcoming some of the limitations (e.g.,
a need for additional calculations and minimum increments possible for MDI-treated
patients). Notably, our suggestion is relatively more conservative when applied to insulin-
resistant individuals using lower CF ranges (e.g., ,30) and more aggressive in the midrange
(e.g., 40 to 75). However, one must consider that the calculations used in our approach are
based on anticipated glucose at 30 minutes. When considering the anticipated glucose at
1 hour, the suggested insulin dose adjustments become more conservative. For example,
a single UP trend arrow indicates that glucose is rising 2 to 3 mg/dL/min. At 30 minutes, the
anticipated glucose would be 60 to 90 mg/dL higher. However, the anticipated glucose could
be as much as 120 to 180 mg/dL at 60 minutes if unexposed to other perturbations. If
a child’s CF was 60, our approach suggests adding 1 U of rapid-acting insulin to the premeal
bolus. The additional 1 U of insulin would be expected to provide additional glucose lowering
of 60 mg/dL over the 60 minutes. Given that the 60-minute anticipated glucose could
potentially be much higher at 1 hour, our suggestion could be considered conservative. The
expected glucose would be closer to target, postprandially, without overcorrecting and
without increasing risk for hypoglycemia. As noted, these recommendations are starting
points and should be readjusted as experience increases and responsiveness is observed and
understood. Conversion: mg/dL3 0.0555=mmol/L. CF, correction factor in mg/dL indicates
glucose lowering per unit of rapid-acting insulin; U, units of rapid-acting insulin.
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Table 4. Case Examples to Put Our Approach Into Practice for Children and Adolescents
TheCaseExamples areApplicable toBothMDIand InsulinPumpTreated Individuals. ExamplesAssume
ICR and CF Values Have Been Accurately Determined by the Patient’s Health Care Team and That the
Patient is Administering Rapid-Acting Insulin for Bolus Doses for Carbohydrate Coverage and
Corrections. Examples Assume the Patients Have Insulin-Requiring Diabetes and Are Using Dexcom
G5 rtCGM.
A A 9-year-old school-age child is about to eat dinner. The CGM indicates that the glucose is above target with
a SINGLE UP arrow. A calculated insulin dose is determined using predetermined parameters. Due to the
SINGLE UP arrow and no recent or planned exercise, an adjustment of +0.5 U is suggested. This increases the
total insulin dose to 3.0 U.
Sensor
Glucose
Trend
Arrow
Target
Glucose
Carb Parameters Calculated
Insulin Dose
Trend Arrow
Adjustment
Total
Insulin
Dose
160 mg/dL ↑ 120 mg/dL 50 g CF–80 0.5 U + 2.0 U = 2.5 U +0.5 U 3.0 U
ICR–1:25
B A 16-year-old teen is going to eat breakfast with DOUBLE UP arrows present. Her glucose is below target, and she
uses reverse corrections. An insulin dose is determined using ICR and CF values. Due to DOUBLEUP arrows, an
adjustment of +3.0 U is suggested to account for the rising glucose. This increases the total insulin dose to 12.0 U.
Sensor
Glucose
Trend
Arrow
Target
Glucose
Carb Parameters Calculated
Insulin Dose
Trend Arrow
Adjustment
Total
Insulin
Dose
75 mg/dL ↑↑ 100 mg/dL 70 g CF–25 21.0U+10.0U=9.0U +3.0 U 12.0 U
ICR–1:7
C A 3-year-old toddler is about to eat lunch. The child tends to be a good eater. The parent sees an elevated glucose
with DOUBLE DOWN trend arrows on the CGM display. An insulin dose is calculated based on correction and
carbohydrate intake. Due to the DOUBLE DOWN arrows, a negative adjustment of 20.5 U is suggested to
account for the falling glucose. This decreases the total insulin dose to 2.5 U.
Sensor
Glucose
Trend
Arrow
Target
Glucose
Carb Parameters Calculated
Insulin Dose
Trend Arrow
Adjustment
Total
Insulin
Dose
275 mg/dL ↓↓ 150 mg/dL 40 g CF–125 1.0 U + 2.0 U = 3.0 U 20.5 U 2.5 U
ICR–1:20
D A 7-year-old boy is having lunch at school. His CGM display shows a sensor glucose of 300 mg/dL with SINGLE UP
arrow. The caregiver notes that recess is planned to take place after lunch. An insulin dose is determined that
includes the correction dose and carbohydrate intake. However, due to the planned exercise, using the adjustment
tablemay not be recommended. This conservative approach is suggested because there is typically lessmonitoring
oversight during school hours. (Note: An adjustment may be considered with a parent’s more watchful monitoring
or when exercise is not a factor with a suggested adjustment of +0.5 U, which increases the total insulin dose to 5.5
U. In general, use trend adjustments conservatively in special situations such as exercise.)
Sensor
Glucose
Trend
Arrow
Target
Glucose
Carb Parameters Calculated
Insulin Dose
Trend Arrow
Adjustment
Total
Insulin
Dose
300 mg/dL ↑ 100 mg/dL 60 g CF–100 2.0 + 3.0 = 5.0 U NA (or +0.5 U if
with parents)
5.0 U (or
5.5 U if
with
parents)
ICR–1:20
E A 12-year-old girl just completed afternoon soccer practice. Two hours later, she is preparing for supper, which is
usually a large meal after practice. Her sensor glucose is in range; however, DOUBLE DOWN arrows are also
present. With her parents, she calculates her insulin dose for the planned carbohydrate intake; no correction is
needed. To prevent later hypoglycemia, a negative adjustment of22.0 U is suggested. This decreases the total
insulin dose to 3.0 U.
Sensor
Glucose
Trend
Arrow
Target
Glucose
Carb Parameters Calculated
Insulin Dose
Trend Arrow
Adjustment
Total
Insulin
Dose
105 mg/dL ↓↓ 100 mg/dL 75 g CF–60 5.0 U 22.0 U 3.0 U
ICR–1:15
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Glycemic response to exercise/physical activity can be influenced by the glucose concen-
trations prior to exercise, amount of active insulin during and after exercise, insulin infusion/
injection site, composition of previousmeal, as well as intensity, duration, and type of exercise
[aerobic (e.g., running, swimming, biking) or anaerobic (e.g., resistance training)] [40]. Pe-
diatric patients of all ages may engage in unplanned activities. Notably, most young pediatric
patients engage in aerobic exercise.
Very young patients do not prepare for exercise; they play at any time. School-age/adolescent
patients are more likely to be involved in organized sports, generally in the afternoon after school.
Nocturnal hypoglycemia is particularly common after afternoon exercise [41, 42].
Due to the complexities associated with exercise, we generally suggest refraining from
using our suggested approach during and after exercise. However, trend arrows can be helpful
indicators during exercise to determine when extra carbohydrates are required and can be
used to prevent impending hypoglycemia [43]. A simple approach before and during exercise
when glucose level is#125mg/dL and downward arrow are present may be to ingest between
8 and 30 g of fast-acting carbohydrate and monitor trends carefully. The amount of carbo-
hydrate should be based on several factors including the child’s age, anticipated response to
exercise, and directionality of downward trend arrows (e.g., single downward arrow requires
less carbohydrate than two downward arrows). This should be followed by reassessment of
glucose levels and trend arrows as the exercise continues. The use of trend arrows with
Table 4. Continued
TheCaseExamples areApplicable toBothMDIand InsulinPumpTreated Individuals. ExamplesAssume
ICR and CF Values Have Been Accurately Determined by the Patient’s Health Care Team and That the
Patient is Administering Rapid-Acting Insulin for Bolus Doses for Carbohydrate Coverage and
Corrections. Examples Assume the Patients Have Insulin-Requiring Diabetes and Are Using Dexcom
G5 rtCGM.
F A 5-year-old is preparing for bedtime. His CGM glucose is near his bedtime target of 130 mg/dL and his CGM
shows a SINGLE DOWN arrow. The parents calculate the insulin dose for the bedtime snack and decide no
correction dose is needed with the glucose of 150 mg/dL. They then consider the suggested negative adjustment
of 20.5 U. In this case, the parents decide to decrease the total insulin dose to reduce the risk of nocturnal
hypoglycemia, which brings the net dose to 0.0 U.
Sensor
Glucose
Trend
Arrow
Target
Glucose
Carb Parameters Calculated
Insulin Dose
Trend Arrow
Adjustment
Total
Insulin
Dose
150 mg/dL ↓ 130 mg/dL 15 g CF–120 0.5 U 20.5 U 0.0 U
ICR–1:30
G It is bedtime for a 17-year-old male. Today, he participated in a rigorous hockey tournament. Before going to bed,
he plans to eat a large snack because he is very hungry. His sensor glucose is 210 mg/dL with an ANGLE UP
arrow present. He calculates the insulin dose for the correction and planned carbohydrate intake. He then
considers if he should use the adjustment table following his rigorous exercise that afternoon. He chooses to act
conservatively and not adjust the insulin dose because he is going to bed following an unusually active day. This
decision should reduce his risk of nocturnal hypoglycemia. (Note: An adjustment of 2.0 Umight be added in the
absence of rigorous exercise)
Sensor
Glucose
Trend
Arrow
Target
Glucose
Carb Parameters Calculated
Insulin Dose
Trend Arrow
Adjustment
Total
Insulin
Dose
210 mg/dL b 130 mg/dL 40 g CF–20 4.0 + 5.0 = 9.0 U NA (or +2.0 U if
no exercise)
9.0 U (or
11.0 U
if no
exercise)
ICR–1:8
Calculated Insulin Dose includes insulin needed to cover carbohydrate intake and correction to reach target glucose.
The calculations use the predetermined ICR and CF values and assume these values have been accurately deter-
mined by the patient’s health care team and that the patient is using rapid-acting insulin for carbohydrate intake and
correction.
Abbreviations: CF, correction factor in mg/dL indicates glucose lowering per unit of rapid-acting insulin; U, units of
rapid-acting insulin. Conversion: mg/dL30.0555=mmol/L.
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exercise needs to be individualized to the person and sport and modified according to prior
experience.
C. Sick Day Management
When ill, there is increased risk of hyperglycemia, diabetic ketoacidosis, and acetaminophen
ingestion (intentional or inadvertent). An important concern with rtCGM is falsely elevated
glucose readings due to acetaminophen interference; trend arrows are most impacted during
the onset and tailing off of acetaminophen use [34, 35]. rtCGM users should be aware of each
manufacturer’s recommendations regarding acetaminophen interference. A recent study
reported significant differences between rtCGM and fingerstick glucose readings for up to
6 hours after acetaminophen ingestion [35]. Notably, acetaminophen interference will likely
be eliminated in future CGM models [44].
On sick days, it is advisable to check glucose by confirmatory fingerstick every 2 to 4 hours
and consider insulin correction doses every 2 to 3 hours (with appropriate ketone testing).
Additionally, patients and parents/caregivers should consider using fingerstick monitoring
for treatment decisions when glucose is.250 mg/dL and ketones (blood or urine) are present
and when glucose is ,70 mg/dL or symptoms of hypoglycemia are present.
Patients and parents/caregivers should be counseled to carefully read labels ofmedications
to avoid acetaminophen-containing formulations, and if they choose a medication that
contains acetaminophen, they should base all treatment decisions on fingerstick glucose
values for up to 6 hours following ingestion. A list of common medications that contain
acetaminophen is included in Table 3.
D. Environmental Factors
There are no indications that environmental factors, such as temperature, altitude, or hu-
midity impact rtCGMaccuracy, but they do affect fingerstick blood glucosemonitoring results
[45]. Because accurate calibration is essential to rtCGM accuracy, patients and parents/
caregivers should be advised to perform calibration prior to exposure to these environmental
conditions.
8. Summary
Our goal was to provide a safe, practical approach to using Dexcom G5 trend arrow data. The
approach we present here is based on review of previously published and presented methods.
Instead of percentage or corrective values, our approach focuses on typical insulin sensitivity
ranges and provides a range of adjustments in terms of insulin units that corresponds to
pediatric developmental stages. We believe our simplified approach minimizes the com-
plexity and number of additional steps, and that it will help patients/parents/caregivers
improve glucose control, increase time in range without hypoglycemia, and promote clinical
discussion.
A major difference of pediatric care from adult care is the gradual shift of responsibility
from caregiver to patient. Young children with insulin requiring diabetes rely on parents/
caregivers; whereas older children, adolescents, and young adults must gradually assume
increasing amounts of responsibility for self-care [46]. Transitioning adolescent patients from
pediatric to adult care is often a challenge. Ensuring continuity of care and supporting pa-
tients during transition can involve multiple care teams and changes in therapy or thera-
peutic goals in addition to life challenges. As a starting point, we offer the complementary
approach to adjusting insulin doses using trend arrows in adult patients, which is included in
this issue.
In summary, rtCGM can be a valuable tool for predictive fine-tuning of insulin dosingwhen
“adjusting for the arrows” and for overall diabetes care. With this as a starting point, we hope
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to see more empirically based information and similar guidance developed for other currently
available and emerging glucose monitoring devices.
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